TLRY 1.34 (+2.29%)
US88688T1007Drug ManufacturersDrug Manufacturers - Specialty & Generic

Tilray Brands (TLRY) Competitor Comparison

We are evaluating the key criteria listed to compare Tilray Brands (TLRY) against its competitors in the Drug Manufacturers - Specialty & Generic industry.

Muliplier Rank - TLRY ranking 27 / 54

These are the competitors of Tilray Brands in the industry Drug Manufacturers - Specialty & Generic ranked by muliplier rank
1. Linc LNC
1
2. Eagle Pharmaceuticals EGRX
1
3. Embecta EMBC
1
4. Vifor Pharma G2AB.F
1
5. ProPhase Labs PRPH
1
6. Phibro Animal Health PAHC
0.7
7. Catalent CTLT
0.6
8. Amneal Pharmaceuticals AMRX
0.6
9. Societal CDMO SCTL
0.6
10. Green Thumb Industries R9U2.F
0.6
11. Ayr Wellness 3KJB.F
0.6
12. Zynerba Pharmaceuticals ZYNE
0.6
13. Ascend Wellness Holdings AAWH
0.6
14. Perrigo PRGO
0.6
15. PetIQ PETQ
0.6
16. Procaps Group PROC
0.6
17. Regencell Bioscience Holdings RGC
0.6
18. Teva Pharmaceutical Industries TEVA
0.6
19. Bausch Health Companies BHC
0.6
20. Cumberland Pharmaceuticals CPIX
0.6
21. Curaleaf Holdings CURLF
0.6
22. Elanco Animal Health ELAN
0.5
23. Taro Pharmaceutical Industries TARO
0.4
24. Ironwood Pharmaceuticals IRWD
0.4
25. Organogenesis Holdings ORGO
0.4
26. Theratechnologies THTX
0.2
27. Tilray Brands TLRY
0.2
28. Universe Pharmaceuticals UPC
0.2
29. Zoetis ZTS
0.2
30. Jupiter Wellness JUPW
0.2
31. Alpha Teknova TKNO
0.2
32. Alvotech ALVO
0.2
33. Amphastar Pharmaceuticals AMPH
0.2
34. ANI Pharmaceuticals ANIP
0.2
35. Avadel Pharmaceuticals AVDL
0.2
36. Biofrontera BFRI
0.2
37. Clever Leaves Holdings CLVR
0.2
38. Collegium Pharmaceutical COLL
0.2
39. Cronos Group CRON
0.2
40. Emergent BioSolutions EBS
0.2
41. Evolus EOLS
0.2
42. Flora Growth FLGC
0.2
43. Harrow Health HROW
0.2
44. Journey Medical DERM
0.2
45. Alimera Sciences ALIM
0.2
46. Kamada KMDA
0.2
47. Kolinpharma KIP.MI
0.2
48. Neoleukin Therapeutics NLTX
0.2
49. OptiNose OPTN
0.2
50. Pacira BioSciences PCRX
0.2
51. Relmada Therapeutics RLMD
0.2
52. SCYNEXIS SCYX
0.2
53. Solid Biosciences SLDB
0.2
54. Supernus Pharmaceuticals SUPN
0.2

Obligatory risk notice

We would like to point out that the contents of this website are for general information purposes only and do not constitute recommendations for the purchase or sale of specific financial instruments, and therefore do not constitute investment advice. In particular, marketstorylabs.com and its creators cannot assess the extent to which information / recommendations made on the pages correspond to your investment objectives, your risk tolerance and your ability to bear losses. Therefore, if you make any investment decisions based on information on the site, you do so solely on your own responsibility and at your own risk. This in turn means that neither marketstorylabs.com nor its creators are liable for any losses incurred as a result of investment decisions based on the information on the marketstorylabs.com website or other media used.